Stock Events

Stock Events

NovoCure 

M$275.39
142
-M$0-0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

20FebExpected
Q2 2024
Q3 2024
Q4 2024
-7.43
-6.83
-6.24
-5.64
Expected EPS
-7.11454825182
Actual EPS
N/A

Financials

-40.69%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
8.84BRevenue
-3.6BNet Income

Analyst Ratings

455.61Average Price Target
The highest estimate is 666.41.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCR.MX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zimmer Biomet
ZBH
Mkt Cap17.67B
Zimmer Biomet Holdings, Inc. provides medical devices in orthopedics, a different approach but still in the competitive landscape of comprehensive cancer care solutions.
Intuitive Surgical
ISRG
Mkt Cap170.78B
Intuitive Surgical, Inc. offers robotic-assisted surgical systems, indirectly competing with NovoCure by providing alternative cancer treatment methods.
Medtronic
MDT
Mkt Cap106.97B
Medtronic plc offers medical technologies, services, and solutions, including cancer treatments, competing in the broader oncology market.
Boston Scientific
BSX
Mkt Cap92.25B
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties, including oncology.
Stryker
SYK
Mkt Cap125.43B
Stryker Corporation specializes in medical technologies, including surgical equipment and neurotechnology products that can be used in cancer treatments.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie Inc. is a research-based biopharmaceutical company with a strong portfolio in oncology, directly competing in the cancer treatment market.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. is known for its pharmaceutical products for treating cancer, making it a competitor in the oncology sector.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. is a global biopharmaceutical company with a broad range of oncology treatments, competing in the cancer care market.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the health care field, including cancer treatments.

About

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Show more...
CEO
ISIN
JE00BYSS4X48

Listings

F
DE
038.F
MX
MX
NVCRN.MX
MU
DE
038.MU
STU
DE
038.STU

0 Comments

Share your thoughts

FAQ

What is NovoCure stock price today?▼
The current price of NVCR.MX is M$275.39 MXN — it has decreased by -0% in the past 24 hours. Watch NovoCure stock price performance more closely on the chart.
What is NovoCure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NovoCure stocks are traded under the ticker NVCR.MX.
What is NovoCure revenue for the last year?▼
NovoCure revenue for the last year amounts to 8.84B MXN.
What is NovoCure net income for the last year?▼
NVCR.MX net income for the last year is -3.6B MXN.
In which sector is NovoCure located?▼
NovoCure operates in the Other sector.
When did NovoCure complete a stock split?▼
NovoCure has not had any recent stock splits.